Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease in Both Idiopathic and Induced by LRRK2 Mutation

NCT05355064 is registered in ClinicalTrials.gov with Neuromed IRCCS as lead sponsor.

NCT NCT05355064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05355064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease in Both Idiopathic and Induced by LRRK2 Mutation
Lead sponsor
Neuromed IRCCS
Phase
Phase 4
Overall status
Unknown status
Start date
May 31, 2022
Completion date
May 31, 2023
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease